Key result
Increased stent and glycoprotein IIb/IIIa inhibitor use linked to ~39% fewer repeat PCIs but higher costs.
Why the study?
Does changing clinical practice in PCI between 1998 and 2002 improve clinical outcomes and affect costs in patients undergoing PCI?
Observational (n=2,393)
Yes
Does changing clinical practice in PCI between 1998 and 2002 improve clinical outcomes and affect costs in patients undergoing PCI?
Absolute Event Rate: 5.1% vs 8.4%
p-value: p=0.001
Greater use of stents and glycoprotein IIb/IIIa inhibitors in PCI between 1998 and 2002 reduced the need for repeat revascularization but increased costs, primarily due to longer hospital stays for non-elective cases.
AIM: To assess the effect of changing clinical practice on the costs and outcomes of percutaneous coronary intervention (PCI) between 1998 and 2002. SETTING: Two tertiary interventional centres. PATIENTS: Consecutive patients undergoing PCI over a 12-month period between 1998 and 2002. DESIGN: Comparative observational study of costs and 12-month clinical outcomes of consecutive PCI procedures in 1998 (n = 1047) and 2002 (n = 1346). Clinical data were recorded in the Scottish PCI register. Repeat PCI, coronary artery bypass graft and mortality were obtained by record linkage. Costs of equipment were calculated using a computerised bar-code system and standard National Health Service reference costs. RESULTS: Between 1998 and 2002, the use of bare metal stents increased from 44% to 81%, and the use of glycoprotein IIB/IIIA inhibitors increased from 0% to 14% of cases. During this time, a significant reduction was observed in repeat target-vessel PCI (from 8.4% to 5.1%, p = 0.001), any repeat PCI (from 11.7% to 9.2%, p = 0.05) and any repeat revascularisation (from 15.1% to 11.3%, p = 0.009) within 12 months. Significantly higher cost per case in 2002 compared with 1998 (mean (standard deviation) 2311 pounds (1158) v 1785 pounds (907), p<0.001) was mainly due to increased contribution from bed-day costs in 2002 (45.0% (16.3%) v 26.2% (12.6%), p = 0.01) associated with non-elective cases spending significantly longer in hospital (6.22 (4.3) v 4.6 (4.3) days, p = 0.01). CONCLUSIONS: Greater use of stents and glycoprotein IIb/IIIa inhibitors between 1998 and 2002 has been accompanied by a marked reduction in the need for repeat revascularisation. Longer duration of hospital stay for non-elective cases is mainly responsible for increasing costs. Strategies to reduce the length of stay could considerably reduce the costs of PCI.
No takes yet. Share an insight, caveat, or question.
Denvir et al. (2006) conducted an observational in Coronary artery disease requiring percutaneous coronary intervention (n=2,393). PCI in 2002 vs. PCI in 1998 was evaluated on Repeat target-vessel PCI within 12 months (p=0.001). Changing clinical practice in PCI between 1998 and 2002, including greater use of stents and glycoprotein IIb/IIIa inhibitors, significantly reduced repeat target-vessel PCI from 8.4% to 5.1% but increased mean procedural costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: